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Abstract
Background: Several susceptibility genes have been established for female breast cancer, of which mutations in
BRCA1 and especially in BRCA2 are also known risk factors for male breast cancer (MBC). The role of other breast
cancer genes in MBC is less well understood.
Methods: In this study, we have genotyped 68 MBC patients for the known breast or ovarian cancer associated
mutations in the Finnish population in CHEK2, PALB2, RAD51C, RAD51D, and FANCM genes.
Results: CHEK2 c.1100delC mutation was found in 4 patients (5.9%), which is significantly more frequent than in the
control population (OR: 4.47, 95% CI 1.51–13.18, p = 0.019). Four CHEK2 I157T variants were also detected, but the
frequency did not significantly differ from population controls (p = 0.781). No RAD51C, RAD51D, PALB2, or FANCM
mutations were found.
Conclusions: These data suggest that the CHEK2 c.1100delC mutation is associated with an increased risk for MBC
in the Finnish population.
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Background
Male breast cancer (MBC) is a rare disease comprising
less than 1% of all cancer in men and less than 1% of all
breast cancers, but the incidence is increasing [1].
Associated genetic risk factors for MBC are poorly
understood. Mutations in BRCA1 and especially in
BRCA2 are known risk factors, the prevalence varying in
different MBC populations [1, 2]. According to a study
in 2004, 7.8% of Finnish MBC patients carried a BRCA2
mutation [3]. In Finland, strong founder effects and
enrichment of deleterious alleles are seen [4] and major
founder mutations in BRCA1 and BRCA2 [5] as well as
in other breast and ovarian cancer susceptibility genes
account for the vast majority of the identified mutations.
Mutations in cell-cycle checkpoint kinase 2 (CHEK2) are
associated with an elevated risk for breast cancer [6, 7]. Ap-
proximately 4-fold elevated frequency of a protein truncat-
ing mutation, c.1100delC in exon 10, was found in Finnish
breast cancer patients with a positive family history (5.5%)
compared to population controls (1.4%) and a 6-fold in pa-
tients with bilateral breast cancer compared to patients
with unilateral disease [8]. Among unselected female breast
cancer patients, the mutation was observed at a 2.0% fre-
quency. In a previous study of Finnish MBC patients, the
frequency of the c.1100delC mutation was similar to that
seen in population controls [9] while in a Dutch and an
American study, the frequency was significantly elevated
[10, 11]. Another variant, the missense I157T (c.470T>C)
in the FHA domain of CHEK2, is associated with a milder
elevation in the risk and was observed in 7.4% of unselected
female breast cancer patients, in 5.5% of familial patients,
and in 5.3% of population controls [12]. In a recent study
[13], the incidence of germline mutations in genes mediat-
ing DNA-repair processes among men with metastatic
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prostate cancer was 11.8%, which was significantly higher
than the incidence among men with localized cancer. The
results indicated that a CHEK2 (p < 0.001) or a BRCA2
(p < 0.001) mutation may be associated with an elevated
risk for a more aggressive type of prostate cancer.
Fanconi anemia is a genetically heterogeneous recessive
disorder, which results from biallelic mutations in FA genes,
a family of more than 20 genes involved in DNA repair
[14]. An increased risk of breast or ovarian cancer is associ-
ated with monoallelic mutations in a subset of these genes
(BRCA1, BRCA2, BRIP1, PALB2, RAD51C) [15–20]. In the
Finnish population, founder mutations in BRCA2, PALB2,
and RAD51C genes have been identified [5, 18, 21]. PALB2
c.1592delT mutation has been observed at 0.7–0.9% fre-
quency among Finnish unselected breast cancer patients
and at 2.0–2.7% frequency among familial patients and is
associated with an aggressive breast tumour phenotype [21,
22]. RAD51C mutations c.93delG and c.837+1G>A were
observed at a combined frequency of 1.0% among unse-
lected ovarian cancer patients and at 2.1% frequency among
breast and ovarian cancer families and associated with an
increased risk of ovarian cancer [18]. Neither of the muta-
tions was observed in unselected breast cancer patients.
Mutations in RAD51D are associated with an increased risk
of ovarian cancer [23] and a Finnish founder mutation
c.576+1G>A in the gene was significantly more frequent
among breast cancer patients with a family history of breast
and ovarian cancer (2.9%) than among population controls
(0.1%) [24]. Among Finnish unselected ovarian cancer
patients, the frequency of the c.576+1G>A mutation was
0.6% whereas the frequency among unselected breast can-
cer patients (0.1%) was same as in controls [24]. Finally, a
FANCM nonsense mutation c.5101C>T (p.Q1701X) has
been identified as a susceptibility allele for triple-negative
breast cancer in the Finnish population and was observed
in 2.8% of unselected breast cancer patients and in 3.1% of
breast cancer families [25].
Here we have genotyped the CHEK2 mutations I157T
and c.1100delC, the FANCM mutation p.Q1701X, the
PALB2 mutation c.1592delT, the RAD51C mutations
c.837+1G>A and c.93delG, and the RAD51D mutation
c.576+1G>A in 68 male breast cancer patients. These mu-
tations explain the vast majority of all mutations observed
in these genes in the Finnish population, with only a few
other, very rare or unique mutations identified.
Methods
Patients
We determined the frequency of these mutations in 68
male breast cancer patients. An unselected series of 59
male breast cancer cases was collected at the Helsinki
University Hospital Department of Oncology. Altogether
40 patients, diagnosed with breast cancer in 1997–2007 in
Helsinki (n = 26), Kuopio (n = 2), Oulu (n = 6) and Vaasa
(n = 6), were retrospectively collected in 2009–2012. The
series included 32% of all male breast cancer cases diag-
nosed between 1997 and 2007 and 65% of those patients
who were alive during the collection period. In addition, 19
patients diagnosed between 2008 and 2013 in Helsinki were
collected in 2011–2014 (including 90% of all male breast
cancer cases diagnosed in 2008–2013 in Helsinki). One
male breast cancer case was identified as part of an unse-
lected series of breast cancer patients collected at the
Helsinki University Hospital Department of Surgery in
2001–2004 [26] and eight BRCA1/2 negative male breast
cancer cases diagnosed between 1999 and 2014 were col-
lected at the Helsinki University Hospital Department of
Clinical Genetics in 2002–2014. A written, informed con-
sent and a blood sample were obtained from all subjects.
Clinical data including risk factors, patient and primary
tumour characteristics were obtained by chart review. Obes-
ity was estimated by calculating body mass index (BMI, > 30
obese) from height and weight recorded in patient charts.
Genotyping
We genotyped the RAD51D c.576+1G>A, RAD51C
c.93delG, and RAD51C c.837+1G>A mutations with Taq-
man real-time PCR as described elsewhere [18, 24]. The
PALB2 c.1592delT, the FANCM c.5101C > T, and the
CHEK2 mutations were genotyped with Sanger sequen-
cing using primer pairs described in Additional file 1 for
PCR and ABI BigDyeTerminator 3.1 Cycle Sequencing Kit
(Life Technologies) for the sequencing reactions. The
capillary sequencing was performed at the Institute for
Molecular Medicine Finland (FIMM), University of Helsinki.
For the analysis, we used population control frequencies
in the Finnish population defined in previous studies in
up to 2102 healthy female population controls from
Helsinki (n = 1287) and Tampere (n = 815) area from the
Finnish Red Cross Blood Transfusion Service for the
CHEK2 [8, 12], RAD51D [24], FANCM [25], and RAD51C
mutations [18], and 1079 healthy population controls
from the Helsinki region for the PALB2 mutation [22].
The statistical analysis was done using the SPSS 22 for
MAC. P values for comparisons of male breast cancer
patients and population controls were calculated using
Fisher’s exact test. All P values are two sided.
Results
The median age at diagnosis of breast cancer was
64 years (range 24–90).
The occurrence of risk factors in the studied patients
is presented in Additional file 2. Forty-one patients had
been tested for BRCA mutations, and of these, 2 (4.9%)
were carriers of BRCA1 mutations and 3 (7.3%) carried a
BRCA2 mutation.
The tumour characteristics are described in Table 1.
Nine percent of patients had a T4 tumour. One patient
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had a lobular carcinoma, one an adenocystic carcinoma,
and one a ductal carcinoma in situ whereas all other can-
cers were ductal carcinomas. Most tumours were hor-
mone receptor positive: 91% were estrogen receptor (ER)
positive and 81% progesterone receptor (PR) positive.
The frequencies of mutations detected in this study and
in the control populations are presented in Table 2. The
CHEK2 c.1100delC mutation was found in 4 patients
(5.9%) (odds ratio (OR): 4.47, 95% confidence interval (CI)
1.51–13.18, p = 0.021 compared to population controls).
Median age of the CHEK2 c.1100delC carriers was 56 years
and half of the patients were relatively young at the time
of diagnosis, less than 50 years old (Table 3). All the car-
riers were BRCA1/2 negative and one patient had a family
history of breast cancer. All carcinomas were ductal and
estrogen receptor positive. The I157T variant was also de-
tected in 4 patients (p = 0.781). No RAD51C, FANCM,
PALB2, or RAD51D mutations were found.
Discussion
The CHEK2 c.1100delC mutation associated with an in-
creased risk for MBC in the Finnish population of the
present study. None of the patients with CHEK2
c.1100delC mutation had BRCA1/2 mutation. Mutations
in CHEK2 are known risk factors for female breast can-
cer [7]. The 5.9% mutation frequency detected among
the male breast cancer patients is higher than among the
unselected female patients and comparable to that
among female familial cases (5.5%) [8]. Similar to female
breast cancer [27], the male CHEK2 c.1100delC carrier
tumours were of ductal histology, ER positive, and
poorly differentiated (grade 2–3). The CHEK2
c.1100delC mutation has been also linked to an in-
creased risk for prostate cancer [28], and possibly indi-
cates an elevated risk for metastatic prostate cancer [13].
The role of the CHEK2 c.1100delC mutation as a risk
factor for MBC has been studied in several papers [6, 9–
11, 29–32]. An association between CHEK2 c.1100delC
mutation and MBC risk has been reported in three stud-
ies [6, 10, 11]. A wide variation in the population
frequency of c.1100delC has been observed, with highest
reported frequencies in the Netherlands (1.3–1.6%) and
in Finland (1.1–1.4%) [7]. The rarity of MBC and the
geographic variation in the frequency of the CHEK2
c.1100delC mutation might explain the differences
between studies on the possible association between the
CHEK2 c.1100delC mutation and MBC. In a previous
Finnish study, the CHEK2 c.1100delC mutation fre-
quency was not significantly elevated in MBC patients,
Table 1 Tumour characteristics
Tumour characteristics No. (of 68) Proportion





Lymph node status Positive 22 32%
Negative 34 50%
Unknown 12 18%
Histologic tumour type Ductal 65 96%
Lobular 1 1%
Other 2 3%
ER status Positive 62 91%
Negative 2 3%
Unknown 4 6%
PR status Positive 55 81%
Negative 6 9%
Unknown 7 10%




Her2 Positive 8 12%
Negative 42 62%
Unknown 18 26%
Table 2 The frequencies of mutations detected in study and control populations
Mutation This study Freqa Controlsb Freqc p-value OR 95% CI Ref
CHEK2 c.1100delC 4 of 68 0.059 26 of 1885 0.014 0.019 4.47 1.51–13.18 8
CHEK2 I157T 4 of 68 0.059 100 of 1885 0.053 0.781 1.12 0.40–3.13 12
PALB2 c.1592delT 0 of 68 0 2 of 1079 0.002 1 n.a. n.a. 22
FANCM p.Q1701X 0 of 68 0 38 of 2080 0.018 0.632 n.a. n.a. 25
RAD51C c.93delG 0 of 68 0 2 of 2086 0.001 1 n.a. n.a. 18
RAD51C c.837+1G>A 0 of 68 0 0 of 2086 0 1 n.a. n.a. 18
RAD51D c.576+1G>A 0 of 68 0 1 of 2102 0 1 n.a. n.a. 24
amutation frequency in this study
bsee cited reference for control populations
cmutation frequency in controls
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and did not seem to affect the age on breast cancer onset
[9]. Only 10.5% of patients in that study had a family his-
tory of female breast or ovarian cancer. In our study, how-
ever, the CHEK2 c.1100delC was significantly more
frequent in the studied population compared to population
controls, despite the smaller sample size. The median age
of the patients with CHEK2 c.1100delC mutation was also
younger than in the whole population studied. Of the 43
patients with known family history, 25% had a positive fam-
ily history of female breast cancer. The population control
frequency to which the previous study compared their re-
sults was the same as the one used in this study. Our find-
ing is in line with the Dutch study where the frequency of
the c.1100delC mutation was significantly elevated com-
pared to that seen in population controls (OR: 4.1, 95% CI
1.2–14.3, p = 0.05) [10], both studies suggesting about four-
to five-fold elevated risk for male breast cancer for the
mutation carriers. Very recently, a large American multi-
gene panel study with 715 MBC patients showed that
CHEK2 c.1100delC was associated with moderately
increased risks of MBC (OR: 3.8, 95% CI 1.7–7.8) [11].
Mutations in RAD51C and RAD51D are rare and have
been primarily linked to an increased risk for ovarian can-
cer [19, 23] rather than breast cancer alone. Previously, no
truncating RAD51C mutations were identified among 97
Italian MBC patients and the American multi-gene panel
study also did not identify any RAD51C mutations
whereas one RAD51D mutation was observed among the
715 MBC patients [11, 33]. PALB2 mutations among
MBC patients are relatively rare (0.8%) in the US popula-
tion but have been associated with a significantly
increased risk of male breast cancer [11]. In this study, we
did not detect the RAD51C, RAD51D, FANCM, or PALB2
mutations among male breast cancer patients. However,
our sample size was small. Given the relatively low fre-
quency of RAD51C, RAD51D, FANCM, and PALB2 muta-
tions among unselected female breast cancer patients, the
absence of the studied mutations in the MBC series was
not unexpected. Larger studies are warranted to better
evaluate the contribution of these genes to MBC suscepti-
bility in the Finnish population.
Conclusions
In conclusion, the CHEK2 c.1100delC mutation is asso-
ciated with an increased risk for MBC in the present
study in Finnish population. In light of previous data
from the Netherlands [10] and USA [11], our study thus
suggests that inclusion of CHEK2 mutation analyses
should be considered as a part of genetic testing of MBC
patients, at least in populations with prevalent
mutations.
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Table 3 Clinical and pathological characteristics of the CHEK2 c.1100delC carriers
Age range at
diagnosis








65–70 1 1 0 Ductal Positive Positive 3 n.a. n.a. n.a. n.a. Negative
45–50 1 0 0 Ductal Positive Negative 2 n.a. Negative Negative Negative Negative
40–45 1 1 0 Ductal Positive Negative 3 Negative Positive n.a. n.a. Negative
75–80 1 0 0 Ductal Positive Positive 2 Positive Negative n.a. n.a. Negative
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